PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2011 | 71 | S |
Tytuł artykułu

The effect of human interleukin-10 on the nitric oxide synthases expression in MPTP- based model of Parkinson's disease

Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Parkinson’s disease (PD) is a progressive degenerative disorder, which etiology and pathogenesis remains unknown. Post mortem analysis of PD brain and studies on neurotoxic animal models of PD have provided evidence to support the involvement of oxidative stress and neuroinflammatory processes in the pathogenesis of PD. The high level of nitric oxide (NO) is produced by iNOS during the neuroinflammatory process caused by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treatment. Under pathological condition NO can easily react with superoxide to form peroxynitrite (ONOOˉ), which is a strong oxidant. In the present study was examined the influence of the increased concentration of IL-10 (an anti-inflammatory cytokine) on the NOS expression in mouse model of PD induced by MPTP. One year-old male C57Bl mice were used in this study. An adeno-associated viral vector expressing the gene for human interleukin-10 (hIL-10) was used to transduce striatal cells 4 weeks prior to MPTP intoxication. Mice were sacrificed at the different time intervals: 1, 7 and 21 days after MPTP injection. Immunohistochemical and western blot analyses provide evidence for the protective properties of AAV2-hIL-10 in the MPTP-induced model of PD. There were reduction in the dopaminergic neuron quantity in SNpc and tyrosine hydroxylase protein in the striatum after MPTP injections, whereas in the group additionally treated with AAV2-hIL10 neuroprotection was observed. Treatment with AAV2-hIL-10 suppressed the MPTP-induced increase in iNOS and 3-nitrotyrosine (3-NT) expression in the midbrain.
Słowa kluczowe
Wydawca
-
Rocznik
Tom
71
Numer
S
Opis fizyczny
p.71
Twórcy
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
  • Department of Neurosurgery, University of California San Francisco, San Francisco, USA
autor
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
autor
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
  • Department of Neurosurgery, University of California San Francisco, San Francisco, USA
  • Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Bibliografia
Uwagi
Rekord w opracowaniu
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.agro-4971bb4a-a230-4e9b-9570-f5799ebfb1a5
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.